NCT03189602

Completed

Pulmonary Artery Involvement in Takayasu's Arteritis

Peking Union Medical College Hospital Source

Compare

Other study identifiers

Sponsor study identifier

PUMCH-Pulmonary arteritis

Study Type

observational

Actual enrollment (reported)

51

Locations

1 country

Sites

1

Timeline

Study Start

January 1, 2014

Actual (reported)

Primary Completion

December 31, 2015

Actual (reported)

Study Completion

December 31, 2015

Actual (reported)

Brief Summary

The purpose of this study is to analyze the clinical manifestations, imaging features, and prognosis-related factors of pulmonary artery (PA) involvement in Takayasu's arteritis (TA), and to explore the early clinical features of PA involvement in TA patients.

Registry Overview

Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.

Recruitment status: completed
Actual enrollment (reported): 51 participants
Study completion date: December 31, 2015
Actual (reported)
Listed locations: 1 countries · 1 sites

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.

Study Start
January 1, 2014
Actual (reported)
Primary Completion
December 31, 2015
Actual (reported)
Study Completion
December 31, 2015
Actual (reported)
First Submitted
June 15, 2017
Actual (reported)
First Posted
June 16, 2017
Actual (reported)

Last Updated: June 16, 2017
Status Verified: June 2017
Last Update Submitted: June 15, 2017

Conditions

Pulmonary Artery Hypertension Takayasu Arteritis

Keywords

Takayasu ArteritisPulmonary artery hypertension

Outcome Measures

Primary Outcomes (1)

Pulmonary Artery Systolic Blood Pressure
Pulmonary artery systolic blood pressure(PASP) assessed by transthoracic echocardiography when admission. PASP\>50mmHg is defined as pulmonary hypertension.
1day

Eligibility Criteria

Age14 Years - 67 Years

Sexall

Healthy VolunteersNo

Age GroupsChild (0-17), Adult (18-64), Older Adult (65+)

Sampling MethodProbability Sample

Study Population

Takayasu's arteritis patients with pulmonary artery involvement

You may qualify if:

Meet the diagnostic criteria of TA as defined by the American College of Rheumatology (ACR).

Sponsors & Collaborators

Peking Union Medical College Hospital
Otherlead

Study Sites (1)

Peking Union Medical College Hospital

Beijing, Beijing Municipality, 100730, China

Related Publications (1)

Yang J, Peng M, Shi J, Zheng W, Yu X. Pulmonary artery involvement in Takayasu's arteritis: diagnosis before pulmonary hypertension. BMC Pulm Med. 2019 Nov 27;19(1):225. doi: 10.1186/s12890-019-0983-7.
PMID: 31775708DERIVED

Biospecimen

Retention: SAMPLES WITHOUT DNA

serum

MeSH Terms

Conditions

Takayasu ArteritisFamilial Primary Pulmonary Hypertension

Condition Hierarchy (Ancestors)

Aortic Arch SyndromesAortic DiseasesVascular DiseasesCardiovascular DiseasesArteritisVasculitisSkin Diseases, VascularSkin DiseasesSkin and Connective Tissue DiseasesHypertension, PulmonaryLung DiseasesRespiratory Tract Diseases

Study Officials

Juhong Shi, M.D
Peking Union Medical College Hospital
STUDY CHAIR

Enrollment

51 participants (actual enrollment reported by the registry).

Study Design

Study Type: observational
Observational Model: CASE ONLY
Time Perspective: RETROSPECTIVE
Sponsor Type: OTHER
Responsible Party: SPONSOR

Study Record Dates

First Submitted

June 15, 2017

First Posted

June 16, 2017

Study Start

January 1, 2014

Actual (reported)

Efficacy and Tolerance of Tocilizumab In Takayasu Arteritis

Phase 3Completed

NCT05749666

Comparison of Tofacitinib and Prednisolone in the Treatment of Active Takayasu's Arteritis

Phase 3Unknown

NCT05151848

Comparison of Adalimumab and Tofacitinib in the Treatment of Active Takayasu Arteritis

Phase 4Unknown

NCT07149805

Surgery Benefits Takayasu Arteritis With Stenosis in the Descending Aorta

Completed

NCT05102448

Comparison of Tofacitinib and Methotrexate in Takayasu's Arteritis

Phase 4Recruiting

NCT07500467

Upadacitinib for Refractory Takayasu Arteritis

Completed

PA involvement: meet at least one of three items: (1) at least one of computed tomographic pulmonary angiography (CTPA), pulmonary perfusion imaging, or pulmonary arteriography suggests thickening of vessel wall, stenosis, aneurysm, or occlusion; (2) 18F-fluorodeoxyglucose positron emission tomography/computed tomography (PET/CT) suggests high intake of local radioactive material in pulmonary artery wall; (3) pulmonary artery systolic blood pressure is higher than 50 mmHg assessed by transthoracic echocardiography (defined as PAH), without left ventricular disease.

Contact the study team to confirm eligibility.

Primary Completion

December 31, 2015

Actual (reported)

Study Completion

December 31, 2015

Actual (reported)

Last Updated

June 16, 2017

Record last verified: 2017-06

Data Sharing

IPD Sharing: Will share

Source record

Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.

Source: ClinicalTrials.gov.

JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.

Registry identifier: NCT03189602
Data provider: ClinicalTrials.gov
Source updated: 2017-06-16
Normalization version: ctgov-legacy-1

Open registry record

Source retrieved: 2026-10-25 22:28:28 UTC

Locations

CN(1)

Brief Summary

Registry Overview

Trial Relationships

Related Scientific Literature

Study Timeline

Study Start

Primary Completion

Study Completion

First Submitted

First Posted

Conditions

Keywords

Outcome Measures

Primary Outcomes (1)

Eligibility Criteria

You may qualify if:

Sponsors & Collaborators

Study Sites (1)

Related Publications (1)

Biospecimen

MeSH Terms

Conditions

Condition Hierarchy (Ancestors)

Study Officials

Enrollment

Study Design

Study Record Dates

Data Sharing

Source record

Locations